Cargando…
Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
Background: Hepatocellular carcinoma (HCC) is a major cause of morbidity and mortality among patients with cirrhosis. The risk of HCC recurrence after a complete response among patients treated with direct-acting antivirals (DAAs) has not been fully elucidated yet. Aim: To assess the risk of HCC rec...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071154/ https://www.ncbi.nlm.nih.gov/pubmed/33920785 http://dx.doi.org/10.3390/jcm10081694 |
_version_ | 1783683634291539968 |
---|---|
author | Frazzoni, Leonardo Sikandar, Usama Metelli, Flavio Sadalla, Sinan Mazzella, Giuseppe Bazzoli, Franco Fuccio, Lorenzo Azzaroli, Francesco |
author_facet | Frazzoni, Leonardo Sikandar, Usama Metelli, Flavio Sadalla, Sinan Mazzella, Giuseppe Bazzoli, Franco Fuccio, Lorenzo Azzaroli, Francesco |
author_sort | Frazzoni, Leonardo |
collection | PubMed |
description | Background: Hepatocellular carcinoma (HCC) is a major cause of morbidity and mortality among patients with cirrhosis. The risk of HCC recurrence after a complete response among patients treated with direct-acting antivirals (DAAs) has not been fully elucidated yet. Aim: To assess the risk of HCC recurrence after DAA therapy for hepatitis C virus (HCV). Methods: A systematic review across PubMed, Scopus and Scholar up to November 2020, including full-text studies that assessed the pattern of HCC recurrence after DAA therapy for HCV. Random-effect meta-analysis and univariable metaregression were applied to obtain pooled estimates for proportions and relative risk (RR) and variables influential for the outcome, respectively. Results: Thirty-one studies with 2957 patients were included. Overall, 30% (CI, 26–34%) of the patients with a history of HCC experienced HCC recurrence after DAA therapy, at mean time intervals ranging from 4 to 21 months. This result increased when going from European studies (23%, CI, 17–28%) to US studies (34%, CI, 30–38%), to Egyptian studies (37%, CI, 27–47%), and to Asian studies (33%, CI, 27–40%). Sixty-eight percent (CI, 45–91%) of recurrent HCCs developed within 6 months of follow-up since DAA treatment, among the eight studies providing stratified data. Among the studies providing head-to-head comparisons, the HCC recurrence risk was significantly lower after DAA therapy than IFN (RR, 0.64; CI, 0.51–0.81), and after DAA therapy than no intervention (RR, 0.68; CI, 0.49–0.94). Conclusions: The recurrence of HCC after DAA is not negligible, being higher soon after the end of treatment and among non-European countries. DAA therapy seems to reduce the risk of HCC recurrence compared to an IFN regimen and no intervention. |
format | Online Article Text |
id | pubmed-8071154 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80711542021-04-26 Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis Frazzoni, Leonardo Sikandar, Usama Metelli, Flavio Sadalla, Sinan Mazzella, Giuseppe Bazzoli, Franco Fuccio, Lorenzo Azzaroli, Francesco J Clin Med Review Background: Hepatocellular carcinoma (HCC) is a major cause of morbidity and mortality among patients with cirrhosis. The risk of HCC recurrence after a complete response among patients treated with direct-acting antivirals (DAAs) has not been fully elucidated yet. Aim: To assess the risk of HCC recurrence after DAA therapy for hepatitis C virus (HCV). Methods: A systematic review across PubMed, Scopus and Scholar up to November 2020, including full-text studies that assessed the pattern of HCC recurrence after DAA therapy for HCV. Random-effect meta-analysis and univariable metaregression were applied to obtain pooled estimates for proportions and relative risk (RR) and variables influential for the outcome, respectively. Results: Thirty-one studies with 2957 patients were included. Overall, 30% (CI, 26–34%) of the patients with a history of HCC experienced HCC recurrence after DAA therapy, at mean time intervals ranging from 4 to 21 months. This result increased when going from European studies (23%, CI, 17–28%) to US studies (34%, CI, 30–38%), to Egyptian studies (37%, CI, 27–47%), and to Asian studies (33%, CI, 27–40%). Sixty-eight percent (CI, 45–91%) of recurrent HCCs developed within 6 months of follow-up since DAA treatment, among the eight studies providing stratified data. Among the studies providing head-to-head comparisons, the HCC recurrence risk was significantly lower after DAA therapy than IFN (RR, 0.64; CI, 0.51–0.81), and after DAA therapy than no intervention (RR, 0.68; CI, 0.49–0.94). Conclusions: The recurrence of HCC after DAA is not negligible, being higher soon after the end of treatment and among non-European countries. DAA therapy seems to reduce the risk of HCC recurrence compared to an IFN regimen and no intervention. MDPI 2021-04-15 /pmc/articles/PMC8071154/ /pubmed/33920785 http://dx.doi.org/10.3390/jcm10081694 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Frazzoni, Leonardo Sikandar, Usama Metelli, Flavio Sadalla, Sinan Mazzella, Giuseppe Bazzoli, Franco Fuccio, Lorenzo Azzaroli, Francesco Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis |
title | Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis |
title_full | Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis |
title_fullStr | Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis |
title_full_unstemmed | Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis |
title_short | Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis |
title_sort | hepatocellular carcinoma recurrence after hepatitis c virus therapy with direct-acting antivirals. a systematic review and meta-analysis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071154/ https://www.ncbi.nlm.nih.gov/pubmed/33920785 http://dx.doi.org/10.3390/jcm10081694 |
work_keys_str_mv | AT frazzonileonardo hepatocellularcarcinomarecurrenceafterhepatitiscvirustherapywithdirectactingantiviralsasystematicreviewandmetaanalysis AT sikandarusama hepatocellularcarcinomarecurrenceafterhepatitiscvirustherapywithdirectactingantiviralsasystematicreviewandmetaanalysis AT metelliflavio hepatocellularcarcinomarecurrenceafterhepatitiscvirustherapywithdirectactingantiviralsasystematicreviewandmetaanalysis AT sadallasinan hepatocellularcarcinomarecurrenceafterhepatitiscvirustherapywithdirectactingantiviralsasystematicreviewandmetaanalysis AT mazzellagiuseppe hepatocellularcarcinomarecurrenceafterhepatitiscvirustherapywithdirectactingantiviralsasystematicreviewandmetaanalysis AT bazzolifranco hepatocellularcarcinomarecurrenceafterhepatitiscvirustherapywithdirectactingantiviralsasystematicreviewandmetaanalysis AT fucciolorenzo hepatocellularcarcinomarecurrenceafterhepatitiscvirustherapywithdirectactingantiviralsasystematicreviewandmetaanalysis AT azzarolifrancesco hepatocellularcarcinomarecurrenceafterhepatitiscvirustherapywithdirectactingantiviralsasystematicreviewandmetaanalysis |